Program
Invivo CAR-T
Its studies are mostly in Burkitt Lymphoma · Multiple Myeloma, led by Chongqing Precision Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Precision Biotech | 22 open or running | phase 1since Nov 16, 2025 | Nov 16, 2025 | Dec 31, 2027phase 1 · NCT07239323 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2025First study: phase 1 study in Burkitt LymphomaFirst studyNCT07239323 · 24 planned · China
- Jul 14, 2026Phase 1 study in RecurrenceNCT07715630 · 15 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Burkitt LymphomaNCT07239323
- Apr 30, 2028Primary completion: phase 1 study in RecurrenceNCT07715630
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07715630Recurrence · China | 1 | Recruiting | Apr 30, 2028 | 15 |
| NCT07239323Burkitt Lymphoma · China | 1 | Recruiting | Dec 31, 2027 | 24 |
How it is read
Names in the registry
- “Invivo CAR-T”, 2 entries
Conditions, from the studies’ own filings
- Burkitt Lymphoma, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.